Presentations | Documents
| Year | Title | Description | Download |
|---|---|---|---|
| 2020 | Polypharmacy from a clinical perspective | UNICOM partner Prof. Dr. R. Vander Stichele, Clinical pharmacologist at Ghent University, Belgium/ Senior Research Coordinator at I~HD, explains Polypharmacy concepts from a clinical perspective in the Horizon 2020 project C3-Cloud Webinar on 28 August 2020 | PDF File |
| 2020 | White Paper written by nine SDOs, including CDISC, CEN, DICOM, GS1, HL7, IHE, ISO, LOINC and SNOMED International forming the Joint Initiative Council. | Highlights from the JIC white paper include four standards-based initiatives that offer practical solutions to real-world problems. These initiatives include the International Patient Summary (IPS), the Identification of Medicinal Products (IDMP), COVID-19 and Genomics. The Joint Initiative Council’s SDOs work collaboratively to provide global, coordinated—not competitive—standards that address real-world healthcare issues. | PDF File |
| 2020 | Presentation of UNICOM at SNOMED virtual expo-October 2020 - by Robert Stegmee and Jane Millar | The presentation describes the global problems tackled by UNICOM focusing more specifically on the relationship between IDMP and related terminologies. It explores also the role of SNOMED CT in this and informs about the ressources available to engage with the project. | PDF File |
| 2020 | Initial Gap Analysis on Standards Development -Presentation at HL7 International Work Group Biomedical Research & Regulation (BR&R) September 2020 | Those 4 slides briefly summarize the identified gaps in WP1 for the HL7 WG audience | PDF File |
| 2020 | Keynote lecture by Prof. K. A. Stroetmann "Global patient safety through semantic interoperability - the univocal identification of medicinal products | Presentation made at a virtual evnet organized by the Tallinn Health Care College (THCC), Estonia in October 2020 on the theme: "Public Health & Healthcare in the Move — Opportunities and Challenges in Research, Practice and Policy | PDF File |
| 2020 | Commentary written by some UNICOM participants published in the review Vaccine | Commentary published in the open source journal Vaccine on December 5 2020. The authors detail the actions needed to ensure we can track and trace the global use of COVID-19 vaccines. | PDF File |
| 2020 | Pharmaceutical Strategy for Europe (Communication from the EU Commission) | the Commission proposes a new pharmaceutical strategy for Europe. It is a patient-centred strategy that aims to ensure the quality and safety of medicines, while boosting the sector’s global competitiveness. | PDF File |
| 2021 | EHTEL factsheet: Towards a European Data Space for Medicines | This factsheet explains why the concept of European Health Data Spaces is particularly relevant for medicinal products with a focus on pharmacovigilance. It also analyses what has already been done by Member States in this field, with Belgium as an example, and considers the necessary next steps. | PDF File |
| 2021 | Ensuring COVID-19 Vaccine Traceability - Article published in the volume 21 of the review healthmanagement.org by several UNICOM WP leaders. | After the article published in Vaccine highlighted the need for global monitoring of vaccine use, HealthManagement.org has asked the authors about the challenges of implementing such system in practice and possible measures to minimise the accompanying risks. | PDF File |
| 2021 | UNICOM curent status - Presentation for the International Pharmaceutical Regulators Programme (IPRP) on the 24th of February | This slides set presnet to a wide community of regulators on all continents the objectives, opportunities of exchange and expected results o UNICOM. It inists in particular on the standards gap analysis, the logical model and the Products Pilot List. | PDF File |
| 2021 | Use of EDQM to produce PhPID - Presentation at WG6 Pharmacy ISO/CEN on June 2 2021 | Results of an analysis of the terminology of dose forms of the European Directorate for Quality in Medicines (EDQM) Standardized Terms for Dose Form to determine the (administrable) dose form for the production of the Pharmaceutical Product Identification (PHPID) | PDF File |
| 2021 | IDMP in Europe What does it mean for you?I Presentation at the IHE Europe Experience Sessions on June 15. | WP1 provides a global overview of the high level processes at stake while focusing on the most prominent 5 clincial impacts. | PDF File |
| 2021 | Update on UNICOM progresses: 2nd eHMSEG Communities Meeting on May 27 | The presentation provides an update (as of May 2021) on the work and results achioeved by the UNICOM WPs for the eHMSEG community | PDF File |
| 2021 | Second transatlantic meeting: First UNICOM results | On the 16th of November 2021, the CITADHL board organized the second trans-Atlantic workshop to introduce selected UNICOM work packages to US stakeholders. | PDF File |
| 2022 | Presentation of UNICOM to the Gravitate Health Consortium | UNICOM has a priviledged relationship with the IMI project Gravitate Health which involves among others a large number of Pharma companies. | PDF File |
| 2022 | Scientific article published in APPLIED SCIENCE: How Granular Can a Dose Form Be Described? ConsideringEDQM Standard Terms for a Global Terminology | The aim of the article is (1) to analyse the features of the EDQM terminology, (2) to formulate proposals for minor changes and (3) to create a small ontology of dose forms, based on characteristics of EDQM, and suitable for alignment with other dose form terminologies | PDF File |
| 2022 | Medicinal Product Data Standardisation – Prerequisite for Efficient Data Exchange Between Stakeholders and Impact on the (Inter)National Health Systems: Experience from Croatia | The National Medicinal ¨Products Agency of Croatia explains in details its migration journey to IDMP | PDF File |
| 2022 | EMA eAF Portal (DADI) guide to registration. | The guide aims to support the users of the eAF Portal in completing the registration steps before accessing the platform. Most of these steps are independent from the eAF Portal and correspond to those to obtain registration to use other European Medicines Agency (EMA) systems, such as Management Services for Substances, Products, Organisation and Referentials (SPOR). | PDF File |
| 2022 | Scientific article published in International Journal of Medical Informatics Volume 165, September 2022, 104826 | Analyis of alignment of two standard terminologies for dosage form: RxNorm from the National Library of Medicine for the United States and EDQM from the European Directorate for the Quality in Medicines and Healthcare for Europe | PDF File |
| 2022 | UNICOM presentation during the IHE connecthaton in Montreux (14 Sept 2022) | Those slides present the current status of the project and the link with IHE testing enviironment | PDF File |
| 2022 | Relevance of EU-SRS to global IDMP implementation and the UNICOM clinical Pilots (F2F meeting of the expert Group of the EU-SRS (Sept)) | Those slides explain how an automated extraction of variables that are crucial for legacy conversion in the agencies ca be performed ( and avoid time-consuming pharmaco-archeology activities). | PDF File |
OpenMedicine
OpenMedicine was a Horizon 2020 funded PHC, Grant agreement No.643796. UNICOM builds on the gaps recognized in OpenMedicine. Some relevant deliverables are listed below for reference as background material.| Year | Title | Description | Download |
|---|---|---|---|
| 2016 | D1.3 Initial openMedicine infostructure | This deliverable’s goal is to present a multi standards framework that underpins solutions to identified issues in epSOS: the EU crossborder health data exchange specifications and its pilot results. In particular the identification of medicinal products and the attention to factors related to multiple contexts are addressed creating an infostructure, based on a multi standards framework. | PDF File |
| 2016 | D2.3 Final identifying and descriptive attributes | This deliverable’s goal is to present the final list of identifying and descriptive attributes of medicinal products. It also gives implementation recommendations based on the materials developed in other openMedicine deliverables. D2.3 has provided relevant input to D3.2, which will extend the attribute lists to special products. | PDF File |
| 2016 | D3.2 Identification and description of special products | This report extends the solution towards supporting the identification and the description of such “special” products. Furthermore, it also presents the definition of alternative and complementary use cases where the unambiguous identification of such medicinal or/and pharmaceutical products is needed. | PDF File |
| 2016 | D4.1 Other descriptive needs, product administration and alternative treatments | This document presents clusters as a tool for grouping products with the same preselected attributes. It explores the concepts behind cluster formation and useful attributes which can help in a cross-border setting for such purpose. | PDF File |
| 2016 | D5.2 Meeting the substitution challenge: Member State regulations and core cross-border issues - results and recommendations | This report reviews the initial openMedicine definitions of substitution and selection of a medicinal product at the point of dispensation in a community/retail pharmacy. the revised analytical framework concerning substitution and selection issues. | PDF File |
| 2016 | D6.3 Recommendations and Implementation Roadmap | This document presents some of the conclusions of the openMedicine project. Two high level and ten action-oriented recommendations are formulated. All of them, except one, address issues related to the univocal identification of a medicine when dispensing in a cross-border context an electronic prescription or when displaying a Patient Summary abroad. One recommendation addresses the issue of "substitution" in the EU. | PDF File |
